| Nov 19 |
COCP: Multiple Upcoming Catalysts…
|
| Nov 15 |
November 2024 US Exchange Standouts: Promising Penny Stocks
|
| Nov 13 |
Cocrystal Pharma GAAP EPS of -$0.49 beats by $0.08
|
| Nov 13 |
Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
|
| Oct 31 |
Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins
|
| Oct 18 |
Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation
|
| Sep 26 |
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
|
| Aug 19 |
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
|
| Aug 19 |
COCP: Topline Results from Phase 2a Study of CC-42344 in 2H24…
|
| Aug 15 |
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
|
